The Lewis lab has had a long interest in the mechanisms of various aspects of diabetic dyslipidemia, including postprandial lipemia, High-density Lipoprotein (HDL) lowering and hypertriglyceridemia. We have also had a long standing interest in the interaction between free fatty acids and pancreatic beta cell dysfunction. Previously, we have performed animal and human mechanistic studies but are now focusing exclusively on human studies. In 2002, working in close collaboration with Dr. Khosrow Adeli (U of T), we made the novel observation that the intestine, in addition to the liver, overproduces lipoproteins in insulin resistant states. In our current CIHR-funded work, we are determining the mechanism of intestinal and hepatic lipoprotein overproduction in insulin resistance and type 2 diabetes. We perform integrative, physiological studies in humans, attempting to determine the regulation of intestinal and hepatic lipoprotein particle production by hormones, nutrients and pharmacological agents.
Gary F Lewis
Diabetes Obes Metab. 2018 Mar 14;:
The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes.
Can J Cardiol. 2017 Dec 15;:
Trends Endocrinol Metab. 2018 Jan 03;:
Can J Diabetes. 2017 Dec;41(6):571-575
Curr Opin Lipidol. 2017 Nov 11;:
Arterioscler Thromb Vasc Biol. 2017 Jul 27;:
Ann Intern Med. 2017 Jul 25;:
Evaluation of the specific effects of intranasal glucagon on circulating glucose and lipid concentrations in healthy males during a pancreatic clamp.
Diabetes Obes Metab. 2017 Jul 20;:
Diabetologia. 2017 Jul 20;:
Impact of bariatric surgery on apolipoprotein C-III levels and lipoprotein distribution in obese human subjects.
J Clin Lipidol. 2017 Mar - Apr;11(2):495-506.e3
Senior Scientist, Toronto General Hospital Research Institute (TGHRI)
Director, Banting and Best Diabetes Centre, University of Toronto
Director, Division of Endocrinology and Metabolism, University of Toronto
Professor, Departments of Medicine and Physiology, University of Toronto